Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma.
In a search for serum markers with prognostic value and specificity for disease activity in Hodgkin's lymphoma, we evaluated the clinical significance of soluble suppressor/cytotoxic T-cell antigen (sCD8), soluble interleukin-2 receptor (sCD25) and soluble Hodgkin's associated antigen (sCD30) levels in the serum of 90 patients with untreated Hodgkin's lymphoma (HD). HD patients in advanced stages had significantly higher sCD8 and sCD25 levels than normal controls. The rate of detectable sCD30, which was absent in healthy controls, depended on stage and histological subtype, and was 22% for the entire group. Low sCD25 levels (< 1000 U/ml) predicted an excellent prognosis (100% event-free survival), while patients with high sCD8 levels (> 750 U/ml) or the demonstration of sCD30 had a poor outcome. Therefore, all three markers have prognostic significance. However, only sCD30 correlated strictly with disease activity and seems to be of value for the follow-up of patients in remission.
Gause
A
A
Medizinische Klinik und Poliklinik, University of Saarland, Germany.
Jung
W
W
Schmits
R
R
Tschiersch
A
A
Scholz
R
R
Pohl
C
C
Hasenclever
D
D
Diehl
V
V
Pfreundschuh
M
M
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D000951:Antigens, Neoplasm / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016827:CD8 Antigens / Q000097:blood*; D016009:Chi-Square Distribution; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D017730:Ki-1 Antigen; D008875:Middle Aged; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012995:Solubility
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D015415:Biomarkers; D016827:CD8 Antigens; D017730:Ki-1 Antigen; D015375:Receptors, Interleukin-2